Literature DB >> 17646457

Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer.

Masoom A Haider1, Theodorus H van der Kwast, Jeff Tanguay, Andrew J Evans, Ali-Tahir Hashmi, Gina Lockwood, John Trachtenberg.   

Abstract

OBJECTIVE: The objective of our study was to compare T2-weighted MRI alone and T2 combined with diffusion-weighted imaging (DWI) for the localization of prostate cancer. SUBJECTS AND METHODS: T2-weighted imaging and DWI (b value = 600 s/mm2) were performed in 49 patients before radical prostatectomy using an endorectal coil at 1.5 T in this prospective trial. The peripheral zone of the prostate was divided into sextants and the transition zone into left and right halves. T2 images alone and then T2 images combined with apparent diffusion coefficient (ADC) maps (T2 + DWI) were scored for the likelihood of tumor and were compared with whole-mount histology results. Fixed window and level settings were used to display the ADC maps. Only tumors with an area of more than 0.13 cm2 (> 4 mm diameter) and a Gleason score of > or = 6 were considered significant. The area under the receiver operating characteristic curve (A(z)) was used to assess accuracy.
RESULTS: In the peripheral zone, the A(z) value was significantly higher (p = 0.004) for T2 plus DWI (A(z) = 0.89) than for T2 imaging alone (A(z) = 0.81). Performance was poorer in the transition zone for both T2 plus DWI (A(z) = 0.78) and T2 (A(z) = 0.79). For the whole prostate, sensitivity was significantly higher (p < 0.001) with T2 plus DWI (81% [120/149]) than with T2 imaging alone (54% [81/149]), with T2 plus DWI showing only a slight loss in specificity compared with T2 imaging alone (84% [204/243] vs 91% [222/243], respectively).
CONCLUSION: Combined T2 and DWI MRI is better than T2 imaging alone in the detection of significant cancer (Gleason score > or = 6 and diameter > 4 mm) within the peripheral zone of the prostate.

Entities:  

Mesh:

Year:  2007        PMID: 17646457     DOI: 10.2214/AJR.07.2211

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  154 in total

1.  Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI.

Authors:  B Nicolas Bloch; Elizabeth M Genega; Daniel N Costa; Ivan Pedrosa; Martin P Smith; Herbert Y Kressel; Long Ngo; Martin G Sanda; William C Dewolf; Neil M Rofsky
Journal:  Eur Radiol       Date:  2012-06-03       Impact factor: 5.315

2.  Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation.

Authors:  Kazuhiro Katahira; Taro Takahara; Thomas C Kwee; Seitaro Oda; Yasuko Suzuki; Shoji Morishita; Kosuke Kitani; Yasuyuki Hamada; Mitsuhiko Kitaoka; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2010-07-18       Impact factor: 5.315

3.  Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T--quantitative correlation with biopsy.

Authors:  Piotr Kozlowski; Silvia D Chang; Ran Meng; Burkhard Mädler; Robert Bell; Edward C Jones; S Larry Goldenberg
Journal:  Magn Reson Imaging       Date:  2010-04-13       Impact factor: 2.546

Review 4.  Diffusion weighted imaging in prostate cancer.

Authors:  Cher Heng Tan; Jihong Wang; Vikas Kundra
Journal:  Eur Radiol       Date:  2010-10-09       Impact factor: 5.315

5.  Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI).

Authors:  Nicola Schieda; Niamh Coffey; Previn Gulavita; Omran Al-Dandan; Wael Shabana; Trevor A Flood
Journal:  Eur Radiol       Date:  2014-04-01       Impact factor: 5.315

6.  Diffusion-weighted MRI of the prostate: advantages of Zoomed EPI with parallel-transmit-accelerated 2D-selective excitation imaging.

Authors:  Kolja M Thierfelder; Michael K Scherr; Mike Notohamiprodjo; Jakob Weiß; Olaf Dietrich; Ullrich G Mueller-Lisse; Josef Pfeuffer; Konstantin Nikolaou; Daniel Theisen
Journal:  Eur Radiol       Date:  2014-08-27       Impact factor: 5.315

7.  3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.

Authors:  Nazanin Hajarol Asvadi; Sohrab Afshari Mirak; Amirhossein Mohammadian Bajgiran; Pooria Khoshnoodi; Pornphan Wibulpolprasert; Daniel Margolis; Anthony Sisk; Robert E Reiter; Steven S Raman
Journal:  Abdom Radiol (NY)       Date:  2018-11

8.  The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.

Authors:  Berrend G Muller; Jurgen J Fütterer; Rajan T Gupta; Aaron Katz; Alexander Kirkham; John Kurhanewicz; Judd W Moul; Peter A Pinto; Ardeshir R Rastinehad; Cary Robertson; Jean de la Rosette; Rafael Sanchez-Salas; J Stephen Jones; Osamu Ukimura; Sadhna Verma; Hessel Wijkstra; Michael Marberger
Journal:  BJU Int       Date:  2013-11-13       Impact factor: 5.588

9.  Evaluation of the accuracy and precision of the diffusion parameter EStImation with Gibbs and NoisE removal pipeline.

Authors:  Benjamin Ades-Aron; Jelle Veraart; Peter Kochunov; Stephen McGuire; Paul Sherman; Elias Kellner; Dmitry S Novikov; Els Fieremans
Journal:  Neuroimage       Date:  2018-08-02       Impact factor: 6.556

Review 10.  Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI.

Authors:  Ryan L Brunsing; Natalie M Schenker-Ahmed; Nathan S White; J Kellogg Parsons; Christopher Kane; Joshua Kuperman; Hauke Bartsch; Andrew Karim Kader; Rebecca Rakow-Penner; Tyler M Seibert; Daniel Margolis; Steven S Raman; Carrie R McDonald; Nikdokht Farid; Santosh Kesari; Donna Hansel; Ahmed Shabaik; Anders M Dale; David S Karow
Journal:  J Magn Reson Imaging       Date:  2016-08-16       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.